CRESCENT BIOPHARMA, INC. (CBIO) Shareholder Equity
- 2026-06-30: Preferred Stock, Value, IssuedUSD $4.00M; Common Stock, Value, IssuedUSD $28.00K; Additional Paid in CapitalUSD $379.16M; Retained Earnings (Accumulated Deficit)USD $-219.93M.
- 2026-03-31: Preferred Stock, Value, IssuedUSD $4.00M; Common Stock, Value, IssuedUSD $28.00K; Additional Paid in CapitalUSD $374.91M; Retained Earnings (Accumulated Deficit)USD $-195.09M.
- 2025-12-31: Preferred Stock, Value, IssuedUSD $4.00M; Common Stock, Value, IssuedUSD $28.00K; Additional Paid in CapitalUSD $370.79M; Retained Earnings (Accumulated Deficit)USD $-171.81M.
- 2025-09-30: Preferred Stock, Value, IssuedUSD (m); Common Stock, Value, IssuedUSD $14.00K; Additional Paid in CapitalUSD $192.04M; Retained Earnings (Accumulated Deficit)USD $-79.41M.
CRESCENT BIOPHARMA, INC. Shareholder Equity
Filed components and totals, with each concept and unit kept separate. Components can overlap; they are not added together. Missing disclosures remain (m). Original concept pages retain their detailed breakdowns and history.
| Period end | Preferred Stock, Value, Issued USD | Common Stock, Value, Issued USD | Additional Paid in Capital USD | Retained Earnings (Accumulated Deficit) USD | Stockholders' Equity Attributable to Parent USD | Adjustments to Additional Paid in Capital, Stock Issued, Issuance Costs USD | APIC, Share-based Payment Arrangement, Option, Increase for Cost Recognition USD | APIC, Share-based Payment Arrangement, Increase for Cost Recognition USD | Adjustments to Additional Paid in Capital, Warrant Issued USD | Additional Paid in Capital, Common Stock USD |
|---|---|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $4.00M | $28.00K | $379.16M | $-219.93M | $163.25M | (m) | (m) | 3 month · $3.96M | (m) | (m) |
| 2026-03-31 | $4.00M | $28.00K | $374.91M | $-195.09M | $183.85M | (m) | 3 month · $5.00K | 3 month · $3.69M | 3 month · $423.00K | (m) |
| 2025-12-31 | $4.00M | $28.00K | $370.79M | $-171.81M | $203.01M | 12 month · $13.06M | (m) | 12 month · $9.00M | 12 month · $4.36M | (m) |
| 2025-09-30 | (m) | $14.00K | $192.04M | $-79.41M | $116.64M | (m) | (m) | 3 month · $1.99M | (m) | (m) |
| 2025-06-30 | (m) | $14.00K | $190.04M | $-54.80M | $139.25M | (m) | (m) | 3 month · $4.07M | (m) | (m) |
| 2025-03-31 | (m) | $64.53K | $500.02M | $-496.71M | $-30.16M | (m) | (m) | 3 month · $466.00K | (m) | (m) |
| 2024-12-31 | (m) | $1.00K | $2.39M | $-17.87M | $-15.48M | (m) | (m) | 3 month · $1.07M 12 month · $4.70M | (m) | (m) |
| 2024-09-30 | (m) | $64.48K | $498.45M | $-487.14M | $-1.30M | (m) | (m) | $69.00K 3 month · $1.14M | (m) | (m) |
| 2024-09-19 | (m) | (m) | (m) | (m) | $0.00 | (m) | (m) | (m) | (m) | (m) |
| 2024-06-30 | (m) | $64.48K | $497.32M | $-477.32M | $20.06M | (m) | (m) | 3 month · $1.21M | (m) | (m) |
| 2024-03-31 | (m) | $64.45K | $496.07M | $-467.22M | $28.91M | (m) | (m) | 3 month · $1.19M | (m) | (m) |
| 2023-12-31 | (m) | $64.39K | $494.84M | $-456.49M | $38.41M | (m) | (m) | 12 month · $3.52M | (m) | (m) |
| 2023-09-30 | (m) | $64.37K | $493.89M | $-447.41M | $46.55M | (m) | (m) | 3 month · $887.84K | (m) | (m) |
| 2023-06-30 | (m) | $64.31K | $492.94M | $-438.20M | $54.80M | (m) | (m) | 3 month · $858.09K | (m) | (m) |
| 2023-03-31 | (m) | $64.25K | $492.06M | $-429.95M | $62.18M | (m) | (m) | 3 month · $870.18K | (m) | (m) |
| 2022-12-31 | (m) | $54.38K | $462.46M | $-419.59M | $42.93M | (m) | (m) | 12 month · $3.86M | (m) | (m) |
| 2022-09-30 | (m) | $52.42K | $457.41M | $-409.34M | $48.12M | (m) | (m) | 3 month · $913.98K | (m) | (m) |
| 2022-06-30 | (m) | $52.42K | $456.49M | $-400.82M | $55.73M | (m) | (m) | 3 month · $963.76K | (m) | (m) |
| 2022-03-31 | (m) | $52.39K | $455.53M | $-387.55M | $68.03M | (m) | (m) | 3 month · $1.08M | (m) | (m) |
| 2021-12-31 | (m) | $52.31K | $454.45M | $-372.90M | $81.60M | (m) | (m) | 12 month · $6.09M | (m) | (m) |
| 2021-09-30 | (m) | $51.74K | $451.99M | $-355.48M | $96.57M | (m) | (m) | 3 month · $1.59M | (m) | (m) |
| 2021-06-30 | (m) | $51.54K | $450.38M | $-338.14M | $112.29M | (m) | (m) | 3 month · $1.56M | (m) | (m) |
| 2021-03-31 | (m) | $51.54K | $448.82M | $-323.74M | $125.12M | (m) | (m) | 3 month · $1.61M | (m) | (m) |
| 2020-12-31 | (m) | $49.02K | $437.64M | $-309.47M | $128.22M | (m) | (m) | 12 month · $6.90M | (m) | (m) |
| 2020-09-30 | (m) | $47.83K | $432.12M | $-293.91M | $138.27M | (m) | (m) | 3 month · $1.69M 9 month · $5.27M | (m) | (m) |
| 2020-06-30 | (m) | $46.71K | $425.89M | $-280.18M | $145.75M | (m) | (m) | 3 month · $1.76M 6 month · $3.58M | (m) | (m) |
| 2020-03-31 | (m) | $43.58K | $414.55M | $-266.11M | $148.49M | (m) | (m) | 3 month · $1.82M | (m) | (m) |
| 2019-12-31 | (m) | $43.47K | $412.60M | $-258.44M | $154.20M | (m) | (m) | 12 month · $6.22M | (m) | (m) |
| 2019-09-30 | (m) | $43.36K | $410.75M | $-243.72M | $167.08M | (m) | (m) | 3 month · $1.59M 9 month · $4.49M | (m) | (m) |
| 2019-06-30 | (m) | $43.19K | $408.98M | $-230.46M | $178.56M | (m) | (m) | 3 month · $1.52M 6 month · $2.90M | (m) | (m) |
| 2019-03-31 | (m) | $43.18K | $407.39M | $-214.63M | $192.79M | (m) | (m) | 3 month · $1.38M | (m) | (m) |
| 2018-12-31 | (m) | $43.16K | $405.97M | $-200.55M | $205.46M | (m) | (m) | 12 month · $4.59M | (m) | (m) |
| 2018-09-30 | (m) | $43.14K | $404.70M | $-186.64M | $218.10M | (m) | (m) | 3 month · $1.17M 9 month · $3.44M | (m) | (m) |
| 2018-06-30 | (m) | $43.05K | $403.02M | $-175.07M | $227.99M | (m) | (m) | 3 month · $1.15M 6 month · $2.27M | (m) | (m) |
| 2018-03-31 | (m) | $42.49K | $401.79M | $-163.79M | $238.04M | (m) | (m) | 3 month · $1.12M | (m) | (m) |
| 2017-12-31 | (m) | $34.36K | $271.94M | $-152.28M | $119.70M | (m) | (m) | 12 month · $3.76M | (m) | (m) |
| 2017-09-30 | (m) | $32.74K | $251.55M | $-143.02M | $108.56M | (m) | (m) | (m) | (m) | (m) |
| 2017-06-30 | (m) | $32.72K | $250.47M | $-135.07M | $115.43M | (m) | (m) | (m) | (m) | (m) |
| 2017-03-31 | (m) | $23.85K | $158.79M | $-126.93M | $31.89M | (m) | (m) | (m) | (m) | (m) |
| 2016-12-31 | (m) | $23.25K | $154.25M | $-118.98M | $35.30M | (m) | (m) | 12 month · $2.96M | (m) | (m) |
| 2016-09-30 | (m) | $23.06K | $152.38M | $-110.65M | $41.75M | (m) | (m) | (m) | (m) | (m) |
| 2016-06-30 | (m) | $23.03K | $151.65M | $-102.79M | $48.88M | (m) | (m) | (m) | (m) | (m) |
| 2016-03-31 | (m) | $19.28K | $129.47M | $-94.72M | $34.77M | (m) | (m) | (m) | (m) | (m) |
| 2015-12-31 | (m) | $19.05K | $127.62M | $-87.17M | $40.47M | (m) | (m) | 12 month · $2.32M | (m) | (m) |
| 2015-09-30 | (m) | $19.04K | (m) | $-78.28M | $48.70M | (m) | (m) | (m) | (m) | $126.97M |
| 2015-06-30 | (m) | $19.02K | (m) | $-71.12M | $55.22M | (m) | (m) | (m) | (m) | $126.32M |
| 2015-03-31 | (m) | $19.01K | $125.84M | $-81.51M | $44.36M | (m) | (m) | (m) | (m) | (m) |
| 2014-12-31 | (m) | $18.94K | $125.18M | $-74.40M | $50.80M | (m) | (m) | 12 month · $1.64M | (m) | $125.18M |
| 2014-09-30 | (m) | $18.89K | $124.69M | $-67.00M | $57.71M | (m) | (m) | (m) | (m) | (m) |
| 2014-06-30 | $0.00 | $18.89K | $124.25M | $-60.39M | $63.88M | (m) | (m) | (m) | (m) | (m) |
| 2014-03-31 | (m) | $18.78K | $123.71M | (m) | $55.35M | (m) | (m) | (m) | (m) | (m) |
| 2013-12-31 | $0.00 | $1.43K | $66.15M | $-63.28M | $2.91M | (m) | (m) | 12 month · $425.69K | (m) | (m) |
| 2012-12-31 | (m) | (m) | (m) | (m) | $12.53M | (m) | (m) | 12 month · $415.21K | (m) | (m) |
| 2011-12-31 | (m) | (m) | (m) | (m) | $8.46M | (m) | (m) | (m) | (m) | (m) |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Indaptus Therapeutics, Inc. (INDP) | United States | $0.537B | |
| Evolus, Inc. (EOLS) | United States | $0.519B | -13.32 |
| ARVINAS, INC. (ARVN) | United States | $0.510B | 58.38 |
| PUMA BIOTECHNOLOGY, INC. (PBYI) | United States | $0.507B | 15.53 |
| CAPRICOR THERAPEUTICS, INC. (CAPR) | United States | $0.499B | -10.81 |
| Ovid Therapeutics Inc. (OVID) | United States | $0.487B | -14.41 |
| Phathom Pharmaceuticals, Inc. (PHAT) | United States | $0.572B | -8.76 |
| ASSEMBLY BIOSCIENCES, INC. (ASMB) | United States | $0.481B | -13,053.96 |
| Altimmune, Inc. (ALT) | United States | $0.593B | -6.43 |
| Monopar Therapeutics (MNPR) | United States | $0.598B | -34.82 |